Clinical trials: Nodular Basal Cell Carcinoma
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.
- Trial name
- NCT05157763
- Testing
- EscharEx 5% (EX-02 formulation)
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediWound Ltd
Nodular Basal Cell Carcinoma
Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)
The goal of this clinical trial is to determine safety, tolerability, pharmacokinetics, preliminary efficacy, and Maximum Tolerable Dose (MTD), of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma…
- Trial name
- NCT07670858
- Testing
- Intralesional FLD-103
- Where
- 10 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Feldan Therapeutics
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.
- Conditions
- Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Nonmelanoma Skin Cancers
- Trial name
- NMSC (NCT04470726)
- Testing
- AIV001, AIV001 suspension
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- AiViva BioPharma, Inc.
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
- Trial name
- NCT00108121
- Testing
- PEP005
- Where
- 10 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Basal Cell Carcinomas
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
This is a double-blind, dose escalating, randomized, vehicle-controlled study designed to compare the efficacy and safety of patidegib gel 2% and 4% applied once or twice daily in comparison with that of vehicle in patients with…
- Trial name
- BCC (NCT02828111)
- Testing
- Patidegib, Vehicle gel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- PellePharm, Inc.
Nodular Basal Cell Carcinoma
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.
- Trial name
- NCT01808950
- Testing
- 0.06% Resiquimod Gel - A, 0.06% Resiquimod Gel - B, 0.06% Resiquimod Gel - C
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 4 people
- Sponsor
- Spirig Pharma Ltd.
Basal Cell Carcinoma
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472108
- Testing
- Photodynamic Therapy (PDT), Metvix cream
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Galderma R&D
Nodular Basal Cell Carcinoma
Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.
This Phase 2 study evaluates the safety and efficacy of microneedle array (MNA) alone and in combination with two dose levels of doxorubicin (100µg and 200µg) in patients with nodular basal cell carcinoma.
- Trial name
- NCT06608238
- Testing
- D-MNA 200µg, D-MNA 100µg, Microneedle Array Alone
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 90 people
- Sponsor
- SkinJect, Inc.
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC (sBCC) and nodular BCC (nBCC) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% LDE225…
- Trial name
- NCT01033019
- Testing
- LDE225 0.75%, Vehicle
- Where
- 4 sites in Australia, Austria
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Nevus Syndrome, Skin Neoplasm
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
The study evaluates whether ASN-002 is safe and effective in the treatment of nodular basal cell carcinoma (nBCC) in patients aged 18 years or over.
- Conditions
- Basal Cell Nevus Syndrome, Skin Neoplasm, Nodular Basal Cell Carcinoma of Skin
- Trial name
- ASN-002-001 (NCT02550678)
- Testing
- ASN-002, 5-FU
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472043
- Testing
- PDT with Metvix 160 mg/g cream
- Where
- 7 sites in Australia
- Volunteers
- 66 people
- Sponsor
- Galderma R&D